A Phase I Study of Entinostat in Combination with Atezolizumab/Carboplatin/Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer


Full Title

A Phase 1 Study of Entinostat in Combination with Atezolizumab / Carboplatin / Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer (NCI 10399) (CIRB)


The purpose of this study is to find the best dose of the drug entinostat that can be given in combination with atezolizumab immunotherapy, carboplatin, and etoposide in patients with previously untreated aggressive lung cancer that has spread (“extensive-stage small cell lung cancer”). Entinostat and etoposide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Atezolizumab may help the immune system attack the cancer and interfere with the ability of tumor cells to grow and spread. Carboplatin is a chemotherapy drug that attaches to DNA and may kill tumor cells.

Giving entinostat in combination with atezolizumab, carboplatin, and etoposide may work better than atezolizumab, carboplatin, and etoposide alone. Entinostat is taken orally (by mouth) and the other medications are given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have extensive-stage small cell lung cancer and be candidates for carboplatin and etoposide therapy.
  • Patients may not have received treatment for metastatic cancer. Any prior therapy for non-metastatic disease must have been completed a year or more before receiving the study treatment.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Charles Rudin at 646-608-2870.